ArticleActa medica academica2022
Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia.
Article in Acta medica academica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Drug response testing for elective carotid artery stenting: Prevalence of non-response to aspirin and clopidogrel and influence on post-interventional occurrence of cerebral ischemia.The neuroradiology journal · 2026Article
- Frequency of Key Pharmacogenes CYP2C9, CYP2C19, CYP2D6, and SLCO1B1 in the Yogyakarta Population: Implications for Precision Prescribing in Indonesia.Clinical pharmacology and therapeutics · 2026Article
- High on-clopidogrel platelet reactivity among diabetic female patients with acute ischaemic stroke.Scientific reports · 2026Article
- Predicting clopidogrel resistance in acute ischemic stroke patients: key clinical insights and a novel diagnostic nomogram.BMC neurology · 2025Article
- Dihydrogeodin fromMarine drugs · 2025Article
- Tubridge flow diverter for the treatment of dissecting aneurysms in the middle cerebral artery.Frontiers in neurology · 2025Article
- The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.BMC neurology · 2024Article
- Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.BMC medical genomics · 2024Article
- Ischemic Stroke: Pathophysiology and Evolving Treatment Approaches.Neuroscience insights · 2024Review
- Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis.Thrombosis journal · 2023Review
- Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients.Vascular health and risk management · 2023Article
- Quantitative Determination of Four Potential Genotoxic Impurities in the Active Pharmaceutical Ingredients in TSD-1 Using UPLC-MS/MS.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile. However, clopidogrel resistance is not uncommon but has not been widely studied in Asia. This study will further assess clopidogrel resistance and its risk factors. MATERIALS AND
methodsA cross-sectional study was conducted at Rumah Sakit Universitas, Indonesia, and Rumah Sakit Cipto Mangunkusumo, Indonesia in 2020-2021. All patients had had at least one episode of ischemic stroke. Clopidogrel resistance was assessed using a VerifyNow assay.
results57 subjects were enrolled in this study. We found 15.8% of subjects were clopidogrel resistant. Gender was significantly associated with clopidogrel resistance, with males having 80% lower clopidogrel resistance (OR 0.2 (95% CI 0.022 - 0.638); P=0.006). Meanwhile, smoking was not associated with clopidogrel responsiveness (P=0.051). We found no association between haemoglobin, blood glucose, HbA1c, cholesterol, liver enzymes, serum urea concentration or creatinine levels and clopidogrel resistance.
conclusionClopidogrel remains an effective treatment to prevent recurrent ischemic stroke in Indonesia. Further studies are needed to assess gene polymorphism and clopidogrel resistance, which may explain the findings of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.